Release Date: August 06, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Cytokinetics Inc CYTK reported strong commercial momentum for Mycorzo in the US, with Q2 dispensed patients nearly tripling to 1,500 and new-to-brand prescription share exceeding 40% by quarter end.
- The company successfully launched Mycorzo in Germany, its first European market, and received marketing authorization and reimbursement guidance in the UK, expanding its global footprint.
- Positive top-line results from the Acacia-HCM Phase 3 trial in non-obstructive HCM met both dual primary endpoints, supporting a potential label expansion and a planned sNDA submission in Q4 2026.
- Physician awareness and engagement are rising, with unaided awareness among high-volume prescribers increasing to 68% and over 2,500 healthcare providers completing REMS certification since launch.
- The company fortified its balance sheet with a public offering generating approximately $760 million in net proceeds, ending Q2 with about $1.7 billion in cash and investments.
- Pipeline progress continues with enrollment advancing in the confirmatory Phase 3 COMET-HF trial for omecamtiv mecarbil and the Phase 1 AMBER-HF study for aficamten, alongside a planned presentation of full Acacia-HCM data at ESC.
Negative Points
- Cytokinetics Inc (CYTK) reported a net loss of $198.8 million for Q2 2026, wider than the $134.4 million loss in the same period of 2025, driven by increased SG&A expenses.
- The company raised its full-year 2026 GAAP combined R&D and SG&A expense guidance to $860-$890 million, up from the prior range, reflecting higher commercial readiness investments.
- Product revenue of $25.3 million remains modest relative to operating expenses, with US net product revenues of $23 million and European contributions of only $2.3 million.
- The launch is still early, with only about 700 unique US prescribers and an average of 3 patients per prescriber, indicating limited depth of prescribing among the broader physician base.
- A significant gap exists between prescriptions written (approximately 2,000 in Q2) and dispensed (1,500), with a lengthy process involving REMS enrollment, benefit investigation, and prior authorization potentially delaying revenue recognition.
- The company faces uncertainty regarding regulatory approval for the NHCM indication, with no guarantee of priority review or successful sNDA submission, and potential label distinctions between OHCM and NHCM remain unclear.
Q & A Highlights
Q: Can you clarify the dispensed versus prescribed numbers for Q2, and is the ratio of dispensed to prescribed consistent between the two quarters?
A: Andrew Callos, EVP and Chief Commercial Officer: We reported 680 prescriptions and 400 dispensed in Q1, and around 2,000 prescriptions and 1,500 dispensed in Q2. The difference represents patients in the process of getting prescriptions filled, which involves REMS enrollment, benefit investigation, and prior authorization, a process that takes several weeks. We are getting over 100 prescriptions per week, and the majority of the difference is pending patients. There is a small mid-single-digit percentage of prescriptions that get canceled.
Q: What will be better understood by physicians and investors after the ESC presentation, and where does the new-to-brand share sit now versus the goal of 50% by year-end?
A: Robert Blum, CEO: At ESC, we will present the full Acacia-HCM data, which will provide a more comprehensive look at the magnitude of changes across all endpoints, including secondary endpoints, and how they tell a consistent, robust story. Andrew Callos, EVP and Chief Commercial Officer: We reported over 40% new-to-brand exit share for Q2 (June). We are seeing a higher proportion of scripts for mycorzo than expected, and while we remain conservative on timing, we are moving swiftly toward the majority share.
Q: Is the overall class growth primarily share capture versus growing the pie, and was there any impact from stocking in the $23 million US revenue figure?
A: Andrew Callos, EVP and Chief Commercial Officer: We are seeing an increase in overall new-to-brand prescription growth. Last year, the class saw about 2,000 new prescriptions per quarter; in Q1 it was around 2,500, and in Q2 it approached 3,000. So we are seeing growth in new patients entering the market. Sung Lee, EVP and CFO: As demand increases, distributors carry inventory commensurate with demand, so this quarter was demand-led, not stocking-driven.
Q: What feedback are you hearing from prescribers who switched from Camzyos, especially regarding efficacy at lower doses, and what percentage of new patients are outside centers of excellence?
A: Andrew Callos, EVP and Chief Commercial Officer: We have a flexible dosing window, and we are seeing it play out in the real world, with some patients dosed as quickly as 2 weeks and others up to 2 months. The majority of our prescribers are in the high CMI category (about 40%), with about 30% low-volume and 30% CMI-naive prescribers. For CMI-naive prescribers, the differentiation points that resonate are the REMS program, dosing flexibility, and lack of DDI monitoring.
Q: How are you thinking about the launch sequencing for OHCM, frontline OHCM (Maple), and NHCM, and how will you message these to doctors?
A: Patty Malek, EVP of R&D: It starts with data dissemination through publications and medical affairs interactions with elite prescribers, followed by educational programs. Andrew Callos, EVP and Chief Commercial Officer: Maple will broaden physicians' horizons on who is an appropriate patient for a CMI, especially for low and naive writers. NHCM, if approved, broadens the spectrum of patients a physician can treat with a single agent. We have our messaging and visual aids cascaded to take advantage of further differentiation as approvals come in.
Q: What is the current penetration of CMIs in the OHCM population, and what do you anticipate peak penetration could be?
A: Andrew Callos, EVP and Chief Commercial Officer: The eligible patient population is around 110,000 to 120,000, with about 200,000 to 250,000 treated patients, putting penetration around 20%. I would anticipate peak penetration in the 60-70% range, depending on access, demonstrated safety, and REMS program changes. Robert Blum, CEO: We have a long way to go, and the denominator could grow as new medicines become available.
Q: Given the pace of enrollment in COMET-HF, how are you thinking about the timeline and what would be clinically meaningful on the primary endpoint?
A: Steve Heitner, SVP and Chief Medical Officer: The pace of enrollment has been pleasing, and we expect to complete enrollment at the beginning of 2027. The interim analysis has a very high bar to stop early, so my expectations for stopping are low. The trial was powered to demonstrate a minimally clinically beneficial effect, with a hazard ratio around 0.86-0.88 for the primary endpoint. We saw more sizable treatment effects in the GALACTIC-HF subgroup, and we hope to see that in COMET as well.
Q: What gets you to over 50% new-to-brand share by year-end, and what do you think the full Acacia data at ESC will do to OHCM prescribing near-term?
A: Andrew Callos, EVP and Chief Commercial Officer: It won't be any one segment; it will be continued utilization across all segments. The definition of velocity accounts is shifting, and we are focusing on academic centers and centers of excellence while also bringing on CMI-naive prescribers. Regarding Acacia, while we can't promote it until approved, the publication of a third positive trial will likely have a halo effect on OHCM prescribing, reinforcing safety and efficacy evidence.
Q: How should we think about persistence as the treated base builds, and could it look different for mycorzo given its differentiated dosing and titration regimen?
A: Andrew Callos, EVP and Chief Commercial Officer: Our expectation is that persistence will be the same, if not slightly better, than Camzyos given the profile of the drug and the programs we have in place. Regarding seasonality, we typically see flattening during the summer months (July and August) and an uptick in the fourth quarter, with minor dips around holidays.
Q: How is the European launch panning out, and what are the expectations for subsequent launches?
A: Robert Blum, CEO: We are committed to making mycorzo available throughout Europe, but we are realistic that the US business is the primary revenue driver. We are off to a great start in Germany. Andrew Callos, EVP and Chief Commercial Officer: It's early, but the data from Germany is at or above expectations
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
